Since RANK expression correlated with the mutant KRas status, we tested whether pharmacologic blockade of RANKL/RANK would affect the in vivo growth of human KRAS mutant lung adenocarcinomas using one patient-derived xenograft (PDX) in immunocompromised NSG (NOD-scid IL2Rγnull) mice. This evidence concerns the gene KRAS and lung adenocarcinoma.